XML 49 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated statements of operations:
202320222021
Net product revenue$28,813.9 $25,462.8 $25,957.9 
Collaboration and other revenue(1)
5,310.2 3,078.6 2,360.5 
Revenue$34,124.1 $28,541.4 $28,318.4 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $191.6 million, $163.4 million, and $175.0 million during the years ended December 31, 2023, 2022, and 2021, respectively.
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
U.S.Outside U.S.
202320222021202320222021
Diabetes and obesity:
Trulicity®
$5,433.3 $5,688.8 $4,914.4 $1,699.2 $1,750.9 $1,557.6 
Mounjaro®
4,834.2 366.6 — 328.9 115.9 — 
Jardiance(1)
1,600.4 1,194.5 807.3 1,144.2 871.5 683.5 
Humalog® (2)
863.2 1,191.9 1,320.7 800.2 868.7 1,132.3 
Humulin®
610.1 730.2 832.9 242.0 289.2 389.6 
Basaglar® (3)
443.1 470.7 588.3 285.2 289.7 304.2 
Baqsimi
645.7 110.4 96.4 31.9 28.9 16.8 
Zepbound®
175.8 — — — — — 
Other diabetes and obesity175.0 158.0 159.3 355.2 338.9 384.8 
Total diabetes and obesity14,780.8 9,911.1 8,719.3 4,886.8 4,553.7 4,468.8 
Oncology:
Verzenio®
2,509.0 1,653.2 834.9 1,354.3 830.3 515.0 
Cyramza®
402.3 351.4 358.1 572.4 620.0 674.8 
Erbitux®
528.9 500.1 481.8 67.6 66.4 66.4 
Tyvyt®
— — — 393.4 293.3 418.1 
Alimta®
72.9 543.7 1,233.9 144.6 384.0 827.5 
Other oncology283.9 169.7 120.1 329.0 254.1 210.7 
Total oncology3,797.0 3,218.1 3,028.8 2,861.3 2,448.1 2,712.5 
Immunology:
Taltz®
1,831.6 1,724.6 1,542.4 928.0 757.4 670.4 
Olumiant® (4)
225.5 148.2 324.1 697.2 682.3 791.0 
Other immunology0.8 20.0 15.3 114.4 12.1 17.6 
Total immunology2,057.9 1,892.8 1,881.8 1,739.6 1,451.8 1,479.0 
Neuroscience:
Zyprexa(5)
79.4 30.4 39.6 1,615.4 306.5 390.7 
Emgality®
482.2 462.8 434.5 196.0 188.1 142.7 
Other neuroscience134.4 119.2 140.7 371.1 439.2 750.3 
Total neuroscience696.0 612.4 614.8 2,182.5 933.8 1,283.7 
Other:
Forteo®
335.5 367.3 441.6 197.7 245.8 360.3 
Cialis®
26.1 35.2 10.6 355.3 552.1 707.9 
COVID-19 antibodies(6)
— 2,008.9 1,978.0 — 14.7 261.4 
Other97.7 144.2 136.1 109.9 151.3 233.9 
Total other459.3 2,555.7 2,566.4 662.9 964.0 1,563.5 
Revenue$21,791.0 $18,190.0 $16,811.0 $12,333.1 $10,351.3 $11,507.4 
Numbers may not add due to rounding.
(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(2) Humalog revenue includes insulin lispro.
(3) Basaglar revenue includes Rezvoglar®.
(4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(5) Zyprexa revenue includes sale of the rights for the olanzapine portfolio.
(6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
202320222021
Revenue(1):
U.S.$21,791.0 $18,190.0 $16,811.0 
Europe6,174.7 4,299.2 4,776.8 
Japan1,672.6 1,747.3 2,367.0 
China1,539.7 1,452.8 1,661.4 
Other foreign countries2,946.2 2,852.0 2,702.2 
Revenue$34,124.1 $28,541.4 $28,318.4 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer or other party
Schedule of Amounts Recorded for Contract Liabilities
The following table summarizes contract liability balances:
 20232022
Contract liabilities$193.6 $219.2